Avisi Technologies has released positive 12-month clinical data on the VisiPlate Aqueous Shunt from the VITA Trial. The VITA ...
Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, presented positive twelve-month clinical data on VisiPlate® Aqueous Shunt from the VITA Trial ...
Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina ...
Sight Sciences’ management is scheduled to present at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 8:20 am PT / 11:20 am ET. Sight Sciences’ management is scheduled to ...
Research and development expenses for the third quarter of 2025 were $52.4 million versus $37.1 million for the comparable quarter in 2024, reflecting an increase in overall clinical expenses ...
SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027Together with SOL-1, these ...
Cash balance of $344.8 million as of September 30, 2025, together with net proceeds of ~$445 million from October 2025 equity offering, with expected runway into 2028 BEDFORD, Mass., Nov. 04, 2025 ...
A preservative-free version of Lumigan gel led to IOP reductions comparable to a preserved version of the ophthalmic solution, with a lower rate of treatment-related ocular adverse events.The study, ...
Patients with glaucoma experience earlier onset of presbyopia than those without the disease, according to research published in Clinical and Experimental Optometry. The findings suggest that glaucoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback